A Randomized, Partially Observer-blind, Dose-escalation, Phase I/II Trial Evaluating the Safety and Immunogenicity of Investigational RNA-based Mpox Vaccine Candidates
Latest Information Update: 17 Mar 2025
At a glance
- Drugs BNT 166a (Primary) ; BNT 166c (Primary)
- Indications Monkeypox
- Focus Adverse reactions
- Sponsors BioNTech
- 13 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 03 Dec 2024 Planned number of patients changed from 64 to 96.
- 03 Dec 2024 Status changed to recruiting.